Oral mucositis in patients after allogeneic stem cells transplantation with fludarabine and melphalan containing FLU/MEL conditioning regimen
Authors:
S. Vokurka; J. Škardová; K. Kabátová-Maxová; K. Steinerová; M. Karas
Authors‘ workplace:
Hematologicko-onkologické odd., Fakultní nemocnice v Plzni
Published in:
Transfuze Hematol. dnes,15, 2009, No. 1, p. 13-16.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Allogeneic stem cells transplantation after reduced intensity conditioning regimen is, due to its lower toxicity, a suitable choice for older and pretreated patients. Characteristics of oral mucositis (OM) were observed in 71 patients after FLU/MEL conditioning regimen with fludarabine total dose 120 mg/m2 and melphalan 140 mg/m2. The OM occurred in 78% of patients with median duration of 12 (1–34) days. OM was significantly more often in women and in patients with melphalan dose ≥3.5 mg/kg. In conclusion, in respect of oral mucosa damage the FLU/MEL conditioning regimen cannot be considered low-toxic. Generally recommended prophylactic cryotherapy should be basic approach implemented into this protocol to help reduce OM.
Key words:
mucositis, oral cavity, allogeneic transplantation, melphalan, toxicity
Sources
1. Rubenstein E, Peterson D, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100: 2026–2046.
2. Sonis S, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19: 2201–2205.
3. Giralt S, Thall PF, Issa K, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.
4. Kröger N, Sayer H, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919–3924.
5. Inamoto Y, Oba T, Miyamura K, et al. Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor. Int J Hematol 2006; 83: 356–62.
6. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93: 257–264.
7. Aisa Y, Mori T, Kudo M, et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer 2005; 13: 266–9.
8. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661–1672.
9. Bolwell BJ, Kalaycio M, Sobecks R, et al. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant 2002; 30: 587–591.
10. Robien K, Schubert M, Bruemmer B, et al. Predictors of Oral Mucositis in Patients Receiving Hematopoietic Cell Transplant for Chronic Myelogenous Leukemia. J Clin Oncol 2004; 22: 1268–1275.
11. Cutler C, Shuli L, Haesook TK, et al. Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens. Blood 2004; 104(Suppl 1): Abstract 351.
12. Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621–625.
13. Bensinger W, Schubert M, Ang KK, et al. Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008; 6 (Suppl 1): 1–21.
14. Vokurka S, Bystricka E, Koza V, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT—results of a randomized multicentre study. Support Care Cancer 2005; 13: 554–558.
15. Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 2005; 103: 1165–1171.
16. Grazziutti ML, Dong L, Miceli MH, et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006; 38: 501–506.
17. Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective Oral Mucositis Audit: Oral Mucositis in Patients Receiving High-Dose Melphalan or BEAM Conditioning Chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519–1525.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2009 Issue 1
Most read in this issue
- Systemic mastocytosis
- Idiopathic thrombocytopenic purpura – pathogenesis, modern therapy, and an analysis of its prevalence, diagnostics and therapy in the South Moravian Region
- Guidelines for the treatment of invasive aspergillosis
- Guidelines for the treatment of invasive candidiasis